{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:35:41Z","timestamp":1787646941410,"version":"build-2736575974"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejim.2026.106950","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:01:42Z","timestamp":1779912102000},"page":"106950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Beyond categorical exclusion: Reclaiming clinical judgment in the use of JAK inhibitors for rheumatoid arthritis"],"prefix":"10.1016","volume":"150","author":[{"given":"Nicola","family":"Farina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejim.2026.106950_bib0001","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/03009742.2024.2353433","article-title":"Retention rates of different Janus Kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort","volume":"53","author":"Farina","year":"2024","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106950_bib0002","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.106950_bib0003","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1093\/rheumatology\/kead395","article-title":"The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort","volume":"63","author":"Tomelleri","year":"2024","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.ejim.2026.106950_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2026.106852","article-title":"Shaping rheumatoid arthritis treatment: clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors. Insights from the AMBI-RA study","author":"Bertola","year":"2026","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2026.106950_bib0005","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejim.2025.02.021","article-title":"Assessment of cardiovascular, thromboembolic and cancer risk in patients eligible for treatment with Janus Kinase inhibitors: the JAK-ERA multidisciplinary consensus","volume":"134","author":"Dagna","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.106950_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103504","article-title":"Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: an international appropriateness study","volume":"23","author":"Solitano","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2026.106950_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1225160","article-title":"The impact of EMA recommendations on the real-life use of Janus Kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events","volume":"14","author":"Favalli","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2026.106950_bib0008","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3899\/jrheum.2023-0145","article-title":"Safety of Janus Kinase inhibitors: a real-world multicenter retrospective cohort study","volume":"50","author":"Lanzillotta","year":"2023","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.ejim.2026.106950_bib0009","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/art.43188","article-title":"Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries","volume":"77","author":"Aymon","year":"2025","journal-title":"Arthritis Rheumatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526002554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526002554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:14:49Z","timestamp":1785719689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526002554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":9,"alternative-id":["S0953620526002554"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106950","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond categorical exclusion: Reclaiming clinical judgment in the use of JAK inhibitors for rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106852","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106950"}}